Effects of MetF Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study.

Diabetes Care. 2019 Oct;42(10):1946-1955.
Effects of MetF Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study.
Sardu C1, Paolisso P2, Sacra C3, Mauro C4, Minicucci F4, Portoghese M5, Rizzo MR2, Barbieri M2, Sasso FC2, D’Onofrio N6, Balestrieri ML6, Calabrò P7, Paolisso G2, Marfella R2.
Author information
1
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy drsarducele@gmail.com.
2
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy.
3
Department of Cardiovascular Diseases, John Paul II Research and Care Foundation, Campobasso, Italy.
4
Department of Cardiovascular Diseases, Antonio Cardarelli Hospital, Naples, Italy.
5
UOC Division of Cardiovascular Surgery, Sassari Hospital, Sassari, Italy.
6
Department of Precision Medicine, University of Campania “Luigi Vanvitelli,” Naples, Italy.
7
Division of Clinical Cardiology, AORN Sant’Anna e San Sebastiano, Caserta, Italy.
Abstract
OBJECTIVE:
To evaluate the effect of MetF therapy on coronary endothelial function and major adverse cardiac events (MACE) in patients with prediabetes with stable angina and nonobstructive coronary stenosis (NOCS).
RESEARCH DESIGN AND METHODS:
MetF therapy may be needed to reduce coronary heart disease risk in patients with prediabetes. A total of 258 propensity score-matched (PSM) patients with stable angina undergoing coronary angiography were enrolled in the study. Data from 86 PSM subjects with normoglycemia (NG), 86 PSM subjects with prediabetes (pre-DM), and 86 PSM subjects with prediabetes treated with MetF (pre-DM MetF) were analyzed. During coronary angiography, NOCS was categorized by luminal stenosis <40% and fractional flow reserve >0.80. In addition, we assessed the endothelial function, measuring coronary artery diameter of left anterior descending coronary (LAD) at baseline and after the infusion of acetylcholine, by means of an intracoronary Doppler guide wire. MACE, as cardiac death, myocardial infarction, and heart failure, was evaluated at 24 months of follow-up.
RESULTS:
At baseline, NG patients had a lower percentage of LAD endothelial dysfunction compared with pre-DM patients (P < 0.05). The pre-DM patients had a higher percentage of endothelial LAD dysfunction as compared with the pre-DM MetF patients (P < 0.05). At the 24th month of follow-up, MACE was higher in pre-DM versus NG (P < 0.05). In pre-DM MetF patients, MACE was lower compared with pre-DM patients (P < 0.05).
CONCLUSIONS:
MetF therapy may reduce the high risk of cardiovascular events in pre-DM patients by reducing coronary endothelial dysfunction.
© 2019 by the American Diabetes Association.
Scientific Updates Sponsored by Endothelix Inc. View Archives of Scientific Updates

LATEST SCIENTIFIC UPDATES

Enhance your patient care with the new office-based vascular function test.

Sign Up for our Webinar Series

Why Should We Measure Endothelial Function?